Mai Capital Management Biogen Inc. Transaction History

Mai Capital Management

  • $10.1 Billion
  • Q3 2024

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024
BUY
$190.52 - $236.72 $5,715 - $7,101
30 Added 2.8%
1,102 $255,000
Q1 2024

May 08, 2024
BUY
$212.02 - $267.71 $26,714 - $33,731
126 Added 13.32%
1,072 $231,000
Q4 2023

Feb 09, 2024
SELL
$222.59 - $267.94 $41,846 - $50,372
-188 Reduced 16.58%
946 $244,000
Q3 2023

Nov 14, 2023
SELL
$253.3 - $285.89 $209,225 - $236,145
-826 Reduced 42.14%
1,134 $291,000
Q2 2023

Aug 02, 2023
SELL
$275.25 - $318.06 $6.52 Million - $7.54 Million
-23,694 Reduced 92.36%
1,960 $558,000
Q1 2023

May 10, 2023
SELL
$256.56 - $292.34 $632,676 - $720,910
-2,466 Reduced 8.77%
25,654 $7.13 Million
Q4 2022

Feb 09, 2023
BUY
$252.44 - $306.72 $2.55 Million - $3.1 Million
10,105 Added 56.09%
28,120 $7.79 Million
Q3 2022

Nov 15, 2022
BUY
$194.69 - $268.46 $3.51 Million - $4.84 Million
18,015 New
18,015 $4.81 Million
Q2 2022

Jul 19, 2022
SELL
$187.54 - $223.02 $216,046 - $256,919
-1,152 Closed
0 $0
Q1 2022

May 10, 2022
BUY
$193.77 - $244.14 $5,813 - $7,324
30 Added 2.67%
1,152 $243,000
Q4 2021

Feb 11, 2022
SELL
$223.92 - $287.77 $19,257 - $24,748
-86 Reduced 7.12%
1,122 $269,000
Q3 2021

Nov 12, 2021
SELL
$282.99 - $369.05 $7,923 - $10,333
-28 Reduced 2.27%
1,208 $342,000
Q2 2021

Jul 19, 2021
SELL
$259.0 - $414.71 $489,510 - $783,801
-1,890 Reduced 60.46%
1,236 $428,000
Q1 2021

May 10, 2021
BUY
$242.95 - $284.63 $83,574 - $97,912
344 Added 12.37%
3,126 $874,000
Q4 2020

Feb 16, 2021
BUY
$236.26 - $355.63 $477,953 - $719,439
2,023 Added 266.53%
2,782 $681,000
Q3 2020

Oct 26, 2020
BUY
$264.77 - $305.71 $200,960 - $232,033
759 New
759 $215,000
Q2 2020

Jul 27, 2020
SELL
$258.66 - $342.55 $236,415 - $313,090
-914 Closed
0 $0
Q4 2019

Feb 03, 2020
SELL
$220.06 - $304.07 $88,684 - $122,540
-403 Reduced 30.6%
914 $271,000
Q3 2019

Oct 29, 2019
SELL
$217.44 - $243.88 $31,963 - $35,850
-147 Reduced 10.04%
1,317 $307,000
Q2 2019

Aug 15, 2019
SELL
$219.29 - $241.72 $204,597 - $225,524
-933 Reduced 38.92%
1,464 $342,000
Q1 2019

Apr 29, 2019
SELL
$216.71 - $338.96 $554,560 - $867,398
-2,559 Reduced 51.63%
2,397 $567,000
Q4 2018

Jan 30, 2019
BUY
$278.5 - $352.75 $164,872 - $208,828
592 Added 13.57%
4,956 $1.49 Million
Q3 2018

Oct 12, 2018
BUY
$293.51 - $383.83 $32,579 - $42,605
111 Added 2.61%
4,364 $1.54 Million
Q2 2018

Aug 16, 2018
BUY
$257.52 - $306.91 $121,806 - $145,168
473 Added 12.51%
4,253 $1.23 Million
Q1 2018

Apr 17, 2018
SELL
$260.13 - $367.91 $219,029 - $309,780
-842 Reduced 18.22%
3,780 $1.04 Million
Q4 2017

Jan 30, 2018
BUY
$307.64 - $344.58 $33,532 - $37,559
109 Added 2.42%
4,622 $1.47 Million
Q3 2017

Oct 12, 2017
BUY
$281.15 - $329.69 $40,766 - $47,805
145 Added 3.32%
4,513 $1.41 Million
Q2 2017

Aug 07, 2017
BUY
N/A
4,368
4,368 $1.19 Million

Others Institutions Holding BIIB

# of Institutions
1,037
Shares Held
126M
Call Options Held
1.13M
Put Options Held
1.43M
View Full List

About BIOGEN INC.

BIIB Quotes by TradingView
  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $21.5B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Mai Capital Management Portfolio

Follow Mai Capital Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mai Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Mai Capital Management with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email